Catalyst Wire Dossier Catalyst Wire Dossier

BI 655064

· Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for BI 655064, covering 2013-11-01 to 2024-03-21. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy [Phase 1]

See pricing